You can view 5 more pages before signing in

EPHESUS trial (thrombosis prophylaxis)

Last reviewed 1 Jan 2018

The EPHESUS trial aimed to determine whether the pentasaccharide fondaparinux was more effective than low-molecular-weight heparin at preventing deep venous thrombosis after elective hip replacement.

The multi-centre, double-blind trial enrolled 2309 consecutive patients, aged over 18 years, undergoing elective hip-replacement surgery. Patients were allocated to postoperative 2.5 mg s/c injections of fondaparinux vs. 40 mg s/c injections of enoxaparin daily.

Reference:

1) Lassen MR, Bauer KA, Eriksson BI, Turpie AG; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. (2002). Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359(9319):1715-20

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.